Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Nottingham University, UK

ESMO 33

12 - 16 Sep 2008

Published: 3 Dec 2008

Views: 17561

Rating:

Save

Prof. Poulam Patel

Extended, escalated dose chemo shows no survival benefit in advanced melanoma.

Categories:
Melanoma & skin

Related Videos

Intraoperative Radiotherapy

Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal

Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...

Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Pembrolizumab demonstrates clinically meaningful improvement in distant...

Dr Georgina Long - The University of Sydney, Sydney, Australia

Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer